Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Accumulated Expenses (2016 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Accumulated Expenses for 16 consecutive years, with $31.5 million as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 12.71% to $31.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $31.5 million through Dec 2025, up 12.71% year-over-year, with the annual reading at $31.5 million for FY2025, 12.71% up from the prior year.
  • Accumulated Expenses hit $31.5 million in Q4 2025 for Ligand Pharmaceuticals, up from $24.1 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $31.5 million in Q4 2025 to a low of $7.3 million in Q2 2023.
  • Historically, Accumulated Expenses has averaged $16.4 million across 5 years, with a median of $15.3 million in 2023.
  • Biggest five-year swings in Accumulated Expenses: plummeted 49.89% in 2023 and later surged 123.84% in 2024.
  • Year by year, Accumulated Expenses stood at $17.6 million in 2021, then fell by 10.8% to $15.7 million in 2022, then decreased by 20.5% to $12.5 million in 2023, then surged by 123.84% to $27.9 million in 2024, then grew by 12.71% to $31.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for LGNDZ at $31.5 million in Q4 2025, $24.1 million in Q3 2025, and $17.5 million in Q2 2025.